Effect of Ravulizumab for Slowing Functional Decline Among Adults With Amyotrophic Lateral Sclerosis

This randomized clinical trial evaluates the safety and efficacy of the terminal complement C5 inhibitor ravulizumab vs placebo in adults with amyotrophic lateral sclerosis.
Source: JAMA Neurology - Category: Neurology Source Type: research